The inhibition of SEMA4D/PlexinB1 signaling has been found to show clear therapeutic effects in multiple types of tumors (Evans et al, 2015), rheumatoid arthritis (Yoshida et al, 2015), multiple sclerosis (Smith et al, 2014), Huntington's disease (Southwell et al, 2015), and stroke (Zhou et al, 2018b) in preclinical studies. This evidence concerns the gene PLXNB1 and juvenile Huntington disease.